We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform
Read MoreHide Full Article
Surmodics, Inc. (SRDX - Free Report) recently announced the successful early clinical use of the company’s Pounce LP (Low Profile) Thrombectomy System.
With the addition of a low-profile device, the Surmodics Pounce thrombectomy platform can effectively remove clots from peripheral arteries with a diameter of 2 mm to 4 mm, including those located below the knee.
Price Performance
For the past six months, SRDX’s shares have rallied 8.0% against the industry’s decline of 2.0%. The S&P 500 increased 6.4% in the same time frame.
Image Source: Zacks Investment Research
More on the News
The Pounce Thrombectomy devices from Surmodics are designed to remove emboli and thrombi from the peripheral artery vasculature without the need for surgery.
The new Pounce LP Thrombectomy System is recommended for use in vessels with diameters between 2 mm and 4 mm, which are common sizes for vessels located below the knee. The Pounce LP System is an addition to the Pounce Thrombectomy System, which was first released in 2021 and is meant to be used in vessels with a diameter of 3.5 mm to 6 mm.
By using the device, acute and subacute thrombus can be eliminated from the mid-peroneal artery below the knee without the need for embolization or additional thrombolytic treatment, which have traditionally been very challenging to remove.
The addition of this new device clearly shows the company’s solid efforts to improve its R&D stature, which has proven to be a key growth driver. It ensures to boost the company’s thrombectomy platform to provide more cost-efficient and effective treatments compared to existing available treatments for clot removal using surgical interventions, as in the case of peripheral artery disease.
Industry Prospects
Per a report by Data Bridge Market Research, the market size for global thrombectomy devices was valued at $1.3 billion in 2022 and is expected to grow at a rate of 5.9%. The market is expected to rise to $2.06 billion by 2030.
It is anticipated that the market for mechanical thrombectomy devices will rise because of the growing need for less invasive surgical procedures and the favorable reimbursement guidelines for cardiovascular and neurovascular operations.
Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) , and Acadia Healthcare (ACHC - Free Report) .
Universal Health Services, sporting a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’s shares have gained 1.9% in the past six months against the industry’s 5% decline.
Integer Holdings, presently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 43.5% in the past year against the industry’s 3.7% decline.
Acadia Healthcare, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.4%. ACHC’s long-term earnings are expected to grow at 11.2%.
Acadia’s shares have gained 11.7% in the past six months against the industry’s decline of 5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform
Surmodics, Inc. (SRDX - Free Report) recently announced the successful early clinical use of the company’s Pounce LP (Low Profile) Thrombectomy System.
With the addition of a low-profile device, the Surmodics Pounce thrombectomy platform can effectively remove clots from peripheral arteries with a diameter of 2 mm to 4 mm, including those located below the knee.
Price Performance
For the past six months, SRDX’s shares have rallied 8.0% against the industry’s decline of 2.0%. The S&P 500 increased 6.4% in the same time frame.
Image Source: Zacks Investment Research
More on the News
The Pounce Thrombectomy devices from Surmodics are designed to remove emboli and thrombi from the peripheral artery vasculature without the need for surgery.
The new Pounce LP Thrombectomy System is recommended for use in vessels with diameters between 2 mm and 4 mm, which are common sizes for vessels located below the knee. The Pounce LP System is an addition to the Pounce Thrombectomy System, which was first released in 2021 and is meant to be used in vessels with a diameter of 3.5 mm to 6 mm.
By using the device, acute and subacute thrombus can be eliminated from the mid-peroneal artery below the knee without the need for embolization or additional thrombolytic treatment, which have traditionally been very challenging to remove.
The addition of this new device clearly shows the company’s solid efforts to improve its R&D stature, which has proven to be a key growth driver. It ensures to boost the company’s thrombectomy platform to provide more cost-efficient and effective treatments compared to existing available treatments for clot removal using surgical interventions, as in the case of peripheral artery disease.
Industry Prospects
Per a report by Data Bridge Market Research, the market size for global thrombectomy devices was valued at $1.3 billion in 2022 and is expected to grow at a rate of 5.9%. The market is expected to rise to $2.06 billion by 2030.
It is anticipated that the market for mechanical thrombectomy devices will rise because of the growing need for less invasive surgical procedures and the favorable reimbursement guidelines for cardiovascular and neurovascular operations.
Surmodics, Inc. Price
Surmodics, Inc. price | Surmodics, Inc. Quote
Zacks Rank & Stocks to Consider
SRDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks to consider in the broader medical space are Universal Health Services (UHS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) , and Acadia Healthcare (ACHC - Free Report) .
Universal Health Services, sporting a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 4.4% for 2024. UHS’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
UHS’s shares have gained 1.9% in the past six months against the industry’s 5% decline.
Integer Holdings, presently carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have rallied 43.5% in the past year against the industry’s 3.7% decline.
Acadia Healthcare, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.4%. ACHC’s long-term earnings are expected to grow at 11.2%.
Acadia’s shares have gained 11.7% in the past six months against the industry’s decline of 5%.